Inhaled therapy lowers mortality in patients with ARDS

PHOENIX — More patients with acute respiratory distress syndrome receiving inhaled EXO-CD24 therapy vs. placebo were free of respiratory failure at day 7 and survived at 6 months, according to data presented at the CHEST Annual Meeting.
“The results were remarkable,” Shiran Shapira, PhD, cofounder and chief scientific and technology officer of Nano24, said during her presentation.
In a randomized, double-blind, placebo-controlled phase 2b study, Shapira and colleagues assessed 90 patients with ARDS of any etiology and stage to determine the safety of inhaled EXO-CD24 vs. placebo (aerosolized

Vedolizumab tops anti-TNF for steroid-free stability in UC

Patients with ulcerative colitis who initiated treatment with vedolizumab spent more time in corticosteroid-free disease stability than those who initiated TNF antagonists, according to data published in JAMA Network Open.
However, rates of hospitalization and colectomy were comparable among patients treated with vedolizumab (Entyvio, Takeda), adalimumab (Humira, AbbVie) and infliximab.
“Most comparative studies in UC stop the clock at the first event, such as remission, treatment failure or [an advanced therapy] switch, but UC is lifelong, and treatment decisions build on one another,”

CAR T-cell therapy reduces lupus disease activity

ORLANDO — Chimeric antigen receptor T-cell therapy was associated with consistent reduction in disease activity in patients with systemic lupus erythematosus, according to a review of clinical studies presented at ACR Convergence.
Studies on the efficacy and safety of CAR T-cell therapy have been limited by small sample sizes, according to researchers. The treatment, which was first introduced in 2022, has shown potential for patients with SLE, lupus nephritis, systemic sclerosis and other autoimmune diseases, but the FDA has highlighted the risks associated with it.
The review of 31 studies